An observational study in Ovarian Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Fudan University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Ovarian Neoplasms by Fudan University — 12 open to participants now, 12 under way, 1 of them phase 3. Ovarian Neoplasms · Fudan University.
Among the 14 studies in Ovarian Neoplasms by Fudan University, this one is one of 3 that started in 2024, is one of 5 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 14th registered.
3,385 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →12 of the 14 studies in Ovarian Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 40–75 · Women only
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18–70 · Women only
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,920 is above the median of 200 across 617 observational studies indexed under Ovarian Neoplasms.
Median enrollment 37 across the 9 interventional studies, 168 across the 5 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Fudan University is the lead sponsor of 1,318 studies on the registry; 646 are open to participants now.
4 of the studies in Ovarian Neoplasms by Fudan University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520074Phase 3Fudan UniversityAdjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | 2027-09 |
| NCT07783022Fudan UniversityReal-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer | 2027-05-30 |
| NCT06925126Fudan UniversityExosome-based Recurrence Score for Post-Treatment Ovarian Cancer | 2027-06-01 |
| NCT06973421Fudan UniversityPhase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Ovarian Neoplasms by Fudan University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
2.2 Secondary Objectives First, to evaluate the real-world safety of niraparib first-line maintenance therapy by assessing adverse events (AEs) and serious adverse events (SAEs). Second, to characterize real-world treatment patterns of niraparib, including patient baseline characteristics, initial dose, time interval from chemotherapy completion to maintenance initiation, dose adjustment, treatment interruption or discontinuation and relevant reasons, as well as concomitant and combination treatments.
2.3 Exploratory Objective To explore the association between homologous recombination deficiency (HRD)-related biomarkers and therapeutic efficacy of niraparib first-line maintenance therapy in real-world settings.
Female patients aged ≥ 18 years with histologically confirmed advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (high-grade serous or high-grade endometrioid adenocarcinoma). Subjects received first-line platinum-based chemotherapy with CR/PR and niraparib first-line maintenance therapy in routine clinical practice. This is a non-interventional real-world cohort study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Niraparib (Tablet)
Niraparib administered as first-line maintenance therapy per routine clinical physician prescription and approved product labeling. The study does not initiate, allocate, or modify treatment for participants.
PFS
Time from initiation of niraparib first-line maintenance therapy to disease progression (per investigator assessment) or death from any cause, whichever occurs first.
Time frame: Up to 36 months after niraparib initiation
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for May 2027, 29 months after the start.
Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 29 months is below that.
Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.